Medco Research Institute LLC, a wholly owned subsidiary of Medco Health Solutions Inc. MHS, and AssureRx Health Inc. today announced the initiation of the PREDICT PSYMEDS pilot to evaluate antidepressant and antipsychotic drug adherence and medical care utilization by Medco members after being genotyped with AssureRx's GeneSightRx, a multi-gene pharmacogenetic profile test.
GeneSightRx measures and analyzes multiple clinically important genetic variants that can help physicians understand the way a patient's unique genetic makeup affects his or her ability to tolerate or effectively respond to certain psychotropic medications.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in